Cargando…
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c‐Met and PIK3R2 via degrading PTPN1 in lung adenocarcinoma
BACKGROUND: Calpain 1 (CAPN1) has been found to be a promoter of cancer progression. PTPN1 as a physiological target molecule of CAPN1 plays a dephosphorylated role on multiple receptor tyrosine kinases. This study aimed to reveal the effects of CAPN1/PTPN1 on malignant phenotype and EGFR‐TKI resist...
Autores principales: | Chen, Yichuan, Tang, Jingqun, Lu, Ting, Liu, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327690/ https://www.ncbi.nlm.nih.gov/pubmed/32395869 http://dx.doi.org/10.1111/1759-7714.13465 |
Ejemplares similares
-
PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target
por: Singh, Shaifali, et al.
Publicado: (2023) -
Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017) -
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation
por: Liu, Shin-Yun, et al.
Publicado: (2016) -
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017) -
An anti-CAPN5 intracellular antibody acts as an inhibitor of CAPN5-mediated neuronal degeneration
por: Wang, Yan, et al.
Publicado: (2017)